Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Next-generation sequencing in the lymphoid malignancies

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.04.16
Views: 3459
Rating:

Dr Aaron Logan - UCSF, San Fransisco, USA

Dr Aaron Logan speaks with ecancertv at AACR 2016 about developments in determining the levels of residual disease presence in patients following treatment.

He reports that, utilising the molecular techniques becoming available, detecting the signs of a patient's deep disease response are an effective predictor of disease free survival.

With novel technologies becoming standardised techniques, the ability to determine a patients cancer clonotype and search for its remission in greater detail than light microscopy alone may make it possible to improve screening, therapy, and response duration.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation